Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00259-013-2603-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
SSTR2-Targeted Theranostics in Hepatocellular Carcinoma.
Cancers (Basel)
January 2025
The Brown Foundation Institute of Molecular Medicine, McGovern Medical School, The University of Texas Health Science Center, Houston, TX 77054, USA.
Background: While the clinical use of radiolabeled somatostatin analogs is well established in neuroendocrine tumors, there is growing interest in expanding their application to other somatostatin receptor 2 (SSTR2)-expressing cancers. This study investigates the potential utility of SSTR2-targeted theranostics in hepatocellular carcinoma (HCC).
Methods: SSTR2 expression in HCC cell lines and clinical samples was evaluated using qRT-PCR, Western blot analysis, and a public dataset.
PET imaging of Mn labeled DOTATATE and DOTAJR11.
Sci Rep
January 2025
Department of Radiology, The University of Alabama at Birmingham, Birmingham, USA.
Manganese-52 is gaining interest as an isotope for PET imaging due to its desirable decay and chemical properties for radiopharmaceutical development. Somatostatin receptor 2 (SSTR2) is significantly overexpressed by neuroendocrine tumors (NETs) and is an important target for nuclear imaging and therapy. As an agonist, [Ga]Ga-DOTATATE has demonstrated significant internalization upon interaction with receptor ligands, whereas [Ga]Ga-DOTA-JR11(as an antagonist) exhibits limited internalization but better pharmacokinetics and increased tumor uptake.
View Article and Find Full Text PDFBiodistribution and Dosimetry Evaluation of the Radiolabeled Somatostatin Receptor Antagonist 68Ga-DATA5m LM4 in Molecular Imaging of Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors Patients.
Clin Nucl Med
January 2025
From the Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
Purpose: This study aimed to assess the biodistribution and radiation dosimetry of 68Ga-DATA5m LM4 in patients with gastroenteropancreatic neuroendocrine tumors.
Patients And Methods: Eight patients (5 females and 3 males) with various gastroenteropancreatic neuroendocrine tumors were included in the study. Each patient underwent 3 whole-body PET scans at 10, 60, and 120 minutes after receiving an IV injection of approximately 162.
Preclinical investigation of [Tb]Tb-DOTATATE and [Tb]Tb-DOTA-LM3 for tumor-targeted alpha therapy.
Eur J Nucl Med Mol Imaging
January 2025
Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, 5232, Switzerland.
Purpose: Terbium-149 is a short-lived α-particle emitter, potentially useful for tumor-targeted therapy. The aim of this study was to investigate terbium-149 in combination with the somatostatin receptor (SSTR) agonist DOTATATE and the SSTR antagonist DOTA-LM3. The radiopeptides were evaluated to compare their therapeutic efficacy in vitro and in vivo.
View Article and Find Full Text PDFRadiochemical purity and patient preparation: Key factors affecting the accuracy of Ga-DOTATOC PET/CT imaging in neuroendocrine tumors.
Hell J Nucl Med
December 2024
Nuclear Medicine-PET/CT Department "Theageneio" Cancer Center, Thessaloniki, Greece.
Gallium-68-DOTA-D-phe1-try3-octreotide (Ga-DOTATOC) positron emission tomography/computed tomography (PET/CT) is a crucial diagnostic tool for neuroendocrine tumors (NET). Its accuracy is influenced by radiochemical purity and patient preparation. We present two cases where unexpected radiotracer uptake in Ga-DOTATOC PET/CT imaging was observed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!